Influence of patient perceptions and preferences for osteoporosis medication on adherence behavior in the Denosumab Adherence Preference Satisfaction study

Menopause

Volumn 21, Issue 1, 2014, Pages 25-32

  Kendler, David L ^a   Macarios, David ^b   Lillestol, Michael J ^c   Moffett, Alfred ^d   Satram Hoang, Sacha ^e   Huang, Joice ^b   Kaur, Primal ^b   Tang, En Tzu ^b   Wagman, Rachel B ^b   Horne, Rob ^f  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b AMGEN INC   (United States)

^c Internal Medicine Associates   (United States)

^d OB GYN Associates of Mid Florida   (United States)

^e QD Research   (United States)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Adherence; Alendronate; Compliance; Denosumab; Perception; Persistence

Indexed keywords

ALENDRONIC ACID; CALCIUM; COLECALCIFEROL; DENOSUMAB;

ADULT; ARTICLE; BELIEFS ABOUT MEDICINES QUESTIONNAIRE; BONE DENSITY; BONE MASS; CALCIUM INTAKE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET SUPPLEMENTATION; DRUG PREFERENCE; DUAL ENERGY X RAY ABSORPTIOMETRY; EXPLORATORY RESEARCH; FEMALE; FEMUR NECK; FRAGILITY FRACTURE; HIGH RISK POPULATION; HIP; HUMAN; INTERACTIVE VOICE RESPONSE SYSTEM; LUMBAR SPINE; MAJOR CLINICAL STUDY; MEDICATION COMPLIANCE; MIDDLE AGED; MULTICENTER STUDY; OPEN STUDY; PATIENT COMPLIANCE; PERCEPTION; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; QUESTIONNAIRE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; VITAMIN SUPPLEMENTATION;

ADMINISTRATION, ORAL; AGED; ALENDRONATE; ANTIBODIES, MONOCLONAL, HUMANIZED; BONE DENSITY CONSERVATION AGENTS; CROSS-OVER STUDIES; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; INJECTIONS, SUBCUTANEOUS; MEDICATION ADHERENCE; MIDDLE AGED; OSTEOPOROSIS; PATIENT PREFERENCE; PERCEPTION; QUESTIONNAIRES;

EID: 84891829053     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/GME.0b013e31828f5e5d     Document Type: Article

References (38)

1. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353:487-497.
2. Cutler DM, Everett W. Thinking outside the pillboxVmedication adherence as a priority for health care reform. N Engl J Med 2010;362: 1553-1555.
3. World Health Organization. Adherence to long-term therapies: evidence for action. Available at: http://www.who.int/chp/knowledge/publications/adherence- report/en/. Accessed December 10, 2012.
4. Ross S, Samuels E, Gairy K, Iqbal S, Badamgarav E, Siris E. Ameta-analysis of osteoporotic fracture risk with medication nonadherence. Value Health 2011;14:571-581.
5. Siris ES, Selby PL, Saag KG, Borgstrom F, Herings RM, Silverman SL. Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med 2009;122:S3-S13.
6. CreeMW, Juby AG, Carriere KC.Mortality and morbidity associated with osteoporosis drug treatment following hip fracture. Osteoporos Int 2003; 14:722-727.
7. Kanis JA, Johnell O, Oden A, et al. The risk and burden of vertebral fractures in Sweden. Osteoporos Int 2004;15:20-26.
8. Strom O, Borgstrom F, Kanis JA, et al. Osteoporosis: burden, health care provision and opportunities in the EU: a report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 2011;6:59-155.
9. Copher R, Buzinec P, Zarotsky V, Kazis L, Iqbal SU, Macarios D. Physician perception of patient adherence compared to patient adherence of osteoporosismedications from pharmacy claims. Curr Med Res Opin 2010;26:777-785.
10. Curtis JR, Carbone L, Cheng H, et al. Longitudinal trends in use of bone mass measurement among older Americans, 1999-2005. J Bone Miner Res 2008;23:1061-1067.
11. Gourlay ML, Preisser JS, Callahan LF, Linville JC, Sloane PD. Survey of osteoporosis preventive care in community family medicine settings. Fam Med 2006;38:724-730.
12. Horne R, Weinman J, Barber N, et al. Report for the National Co-ordinating Centre for NHS Service Delivery and Organisation R&D (NCCSDO). Available at: http://www.netscc.ac.uk/hsdr/files/project/SDO-FR-08- 1412-076-V01.pdf. Accessed March 22, 2013.
13. Horne R. Improving adherence with asthma therapies. In: Advances in Asthma Management. London, England: Future Medicine Ltd, 2012: 132-142.
14. Horne R. Treatment perceptions and self-regulation. In: Cameron LD, Leventhal H, eds. The Self-Regulation of Health and Illness Behaviour. London, England: Routledge; 2003:139-153.
15. Barber N, Safdar A, Franklin BD. Can human error theory explain nonadherence? Pharm World Sci 2005;27:300-304.
16. Boonen S, Adachi JD, Man Z, et al. Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk. J Clin Endocrinol Metab 2011;96:1727-1736.
17. Brown JP, Adachi JD, Kendler DL, Rigal R, Deutsch G, Leclerc JM. A community-based clinical trial of Intra-Venous zOledRonic acid once Yearly in comparison to oral bisphosphonates in postmenopausal women with osteoporosis: the IVORY trial Methodological considerations. Contemp Clin Trials 2011;32:741-746.
18. McClung MR, Balske A, Burgio DE, Wenderoth D, Recker RR. Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years. Osteoporos Int 2013;24:301-310.
19. Horne R. Compliance, adherence, and concordance: implications for asthma treatment. Chest 2006;130:65S-72S.
20. Horne R, Cooper V, Gellaitry G, Date HL, Fisher M. Patients perceptions of highly active antiretroviral therapy in relation to treatment uptake and adherence: the utility of the necessity-concerns framework. J Acquir Immune Defic Syndr 2007;45:334-341.
21. Horne R, Weinman J. Self-regulation and self-management in asthma: exploring the role of illness perceptions and treatment beliefs in explaining non-adherence to preventer medication. Psychol Health 2002;17:17-32.
22. Butler JA, Peveler RC, Roderick P, Smith PW, Horne R, Mason JC. Modifiable risk factors for non-adherence to immunosuppressants in renal transplant recipients: a cross-sectional study. Nephrol Dial Transplant 2004; 19:3144-3149.
23. Neame R, Hammond A. Beliefs about medications: a questionnaire survey of people with rheumatoid arthritis. Rheumatology (Oxford) 2005; 44:762-767.
24. Horne R, Weinman J. Patients beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res 1999;47:555-567.
25. Freemantle N, Satram-Hoang S, Tang ET, et al. Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women. Osteoporos Int 2012;23:317-326.
26. Kendler DL, McClung MR, Freemantle N, et al. Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate. Osteoporos Int 2011;22:1725-1735.
27. Gold DT, Horne R, Coon CD, et al. Development, reliability, and validity of a new Preference and Satisfaction Questionnaire. Value Health 2011; 14:1109-1116.
28. Horne R, Weinman J, Hankins M. The Beliefs about Medicines Questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. Psychol Health 1999;14:1-24.
29. Carmona R, Adachi R. Treatment of postmenopausal osteoporosis, patient perspectivesVfocus on once yearly zoledronic acid. Patient Preference Adherence 2009;3:189-193.
30. Emkey R, Koltun W, Beusterien K, et al. Patient preference for oncemonthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin 2005;21:1895-1903.
31. Hadji P, Minne H, Pfeifer M, et al. Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: a randomized, crossover study (BALTO II). Joint Bone Spine 2008;75:303-310.
32. Hadji P, Ziller V, Gamerdinger D, et al. Quality of life and health status with zoledronic acid and generic alendronateVa secondary analysis of the Rapid Onset and Sustained Efficacy (ROSE) study in postmenopausal women with low bone mass. Osteoporos Int 2012;23:2043-2051.
33. Gold DT. Understanding patient compliance and persistence with osteoporosis therapy. Drugs Aging 2011;28:249-255.
34. Gold DT, Safi W, Trinh H. Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate. Curr Med Res Opin 2006;22:2383-2391.
35. Mazor KM, Velten S, Andrade SE, Yood RA. Older womens views about prescription osteoporosis medication: a cross-sectional, qualitative study. Drugs Aging 2010;27:999-1008.
36. Horne R, Parham R, Driscoll R, Robinson A. Patients attitudes to medicines and adherence to maintenance treatment in inflammatory bowel disease. Inflamm Bowel Dis 2009;15:837-844.
37. Horne R. Your treatment will not work if the patient does not take it. In: Irving P, Siegel C, Rampton D, Shanahan F, eds. Clinical Dilemmas in Inflammatory Bowel Disease: New Challenges, 2nd ed. Chicester, UK: Blackwell Publishing Ltd, 2011:247-250.
38. Donovan JL, Blake DR. Patient non-compliance: deviance or reasoned decision-making? Soc Sci Med 1992;34:507-513.